Flu, Human Clinical Trial
Official title:
Factors Influencing Flu Vaccination in Primary Health Care
This study aims to study the barriers to flu vaccination among at-risk people at the Primary Health Care level in order to increase the vaccination rates as recommended by the World Health Organization.
People from vulnerable groups (e.g., those diagnosed with Diabetes, Chronic Obstructive
Pulmonary Disease, Asthma) are at increased risk of developing complications from infection
with influenza virus, that could ultimately result in death.
Flu vaccination is recommended by many authorities, including the World Health Organization,
as a means to decrease the risk of developing such life-threatening conditions. However,
vaccination rates are well below the recommended threshold.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
| Completed |
NCT03293732 -
Study of the Safety, Tolerability and Immunogenicity of an Intranasal Influenza Vaccine Administered to Healthy Adults
|
Phase 1 | |
| Enrolling by invitation |
NCT03228095 -
Volatiles in Breath and Headspace Analysis - Diagnostic Markers
|
||
| Recruiting |
NCT06278324 -
Effectiveness of a Nasal Spray on Viral Respiratory Infections
|
N/A | |
| Completed |
NCT05312294 -
Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 Years
|
Phase 3 | |
| Completed |
NCT04160975 -
Persuasion in Medicine: Experimental Evidence on Sender and Signal Effects
|
N/A | |
| Completed |
NCT02107807 -
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
|
Phase 3 |